Vaxcyte Inc (PCVX) Stock: A Look at the Analyst Recommendations

MGLD

PCVX has 36-month beta value of 0.92. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for PCVX is 102.89M, and currently, short sellers hold a 8.03% ratio of that float. The average trading volume of PCVX on April 19, 2024 was 841.73K shares.

PCVX) stock’s latest price update

The stock of Vaxcyte Inc (NASDAQ: PCVX) has decreased by -2.90 when compared to last closing price of 62.43. Despite this, the company has experienced a -6.49% fall in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-02 that SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT.

PCVX’s Market Performance

Vaxcyte Inc (PCVX) has experienced a -6.49% fall in stock performance for the past week, with a -10.33% drop in the past month, and a -0.36% drop in the past quarter. The volatility ratio for the week is 3.17%, and the volatility levels for the past 30 days are at 3.27% for PCVX. The simple moving average for the past 20 days is -6.96% for PCVX’s stock, with a 6.05% simple moving average for the past 200 days.

Analysts’ Opinion of PCVX

Many brokerage firms have already submitted their reports for PCVX stocks, with Mizuho repeating the rating for PCVX by listing it as a “Buy.” The predicted price for PCVX in the upcoming period, according to Mizuho is $69 based on the research report published on December 07, 2023 of the previous year 2023.

Needham gave a rating of “Buy” to PCVX, setting the target price at $58 in the report published on January 03rd of the previous year.

PCVX Trading at -13.44% from the 50-Day Moving Average

After a stumble in the market that brought PCVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.11% of loss for the given period.

Volatility was left at 3.27%, however, over the last 30 days, the volatility rate increased by 3.17%, as shares sank -12.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.99% lower at present.

During the last 5 trading sessions, PCVX fell by -6.49%, which changed the moving average for the period of 200-days by +23.19% in comparison to the 20-day moving average, which settled at $64.73. In addition, Vaxcyte Inc saw -3.47% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PCVX starting from Wassil Jim, who sale 3,000 shares at the price of $66.69 back on Apr 01 ’24. After this action, Wassil Jim now owns 218,289 shares of Vaxcyte Inc, valued at $200,066 using the latest closing price.

PICKERING GRANT, the CHIEF EXECUTIVE OFFICER of Vaxcyte Inc, sale 2,616 shares at $66.71 during a trade that took place back on Apr 01 ’24, which means that PICKERING GRANT is holding 147,362 shares at $174,502 based on the most recent closing price.

Stock Fundamentals for PCVX

The total capital return value is set at -0.31. Equity return is now at value -36.67, with -33.33 for asset returns.

Based on Vaxcyte Inc (PCVX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -10.16. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 36.63.

Currently, EBITDA for the company is -382.87 million with net debt to EBITDA at 1.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.54.

Conclusion

To put it simply, Vaxcyte Inc (PCVX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts